Kyverna Therapeutics Inc shares rose as much as 59 percent in early trading on Thursday after its expanded US initial public offering (IPO) raised US$319 million, as drug developers continue to receive a warm welcome from new investors.
Emeryville, California-based Kyverna’s shares gave back some of those gains to end the session at US$30 each in New York, 36 percent above the IPO price of US$22.
At that price, the Bain Capital LP-backed biotechnology company has a market value of about US$1.2 billion.
Photo: Reuters
The opening surge was the biggest for a company raising more than US$100 million in an IPO since Cava Group Inc’s US$365 million debut in June last year, according to data compiled by Bloomberg.
Kyverna had a tough time deciding who to allocate shares to given “very large mutual funds were willing to come into the story and wanted to be part of” the deal, chief executive officer Peter Maag said in an interview. The IPO was about “20-times oversubscribed,” he said.
“This is a tremendous outcome for the organization as it gives us the capital to execute our clinical trial program,” Maag said.
The funds are expected to provide a runway into 2026 and set it up for potential pivotal trials, he said.
The strong results continue a streak of therapeutics companies drawing heightened investor demand.
The offering is the second-largest for a drug developer this year, after cancer-focused CG Oncology Inc raised US$437 million two weeks ago, according to data compiled by Bloomberg. Its shares have more than doubled since its debut.
Kyverna’s lead medicine is a CAR T-cell therapy for autoimmune diseases in rheumatology and neurology. Bain Capital, Gilead Sciences Inc, Vida Ventures LLC and Westlake BioPartners LLC are among Kyverna’s largest investors, according to the company’s filings with the US Securities and Exchange Commission.
Kyverna is part of a busy week for US IPOs that includes American Healthcare REIT Inc, which raised US$672 million and is up nearly 10 percent, and a Mexican grocery chain. Also in biotech, Moderna Inc-backed Metagenomi Inc’s offering was slated to price later on Thursday.
HSBC Innovation Banking managing director Jonathan Norris expects about 25 venture capital-backed biotech IPOs in the US and Europe this year.
There will be “more later-stage than earlier companies with a focus on drugs that have opportunities for catalysts in the near-term,” Norris said.
Drug developers have been actively raising cash through sales of new shares to public investors this year.
The industry has raised nearly US$5 billion via follow-on offerings, data compiled by Bloomberg showed, more than double the amount seen through Feb. 7 last year.
Zhang Yazhou was sitting in the passenger seat of her Tesla Model 3 when she said she heard her father’s panicked voice: The brakes do not work. Approaching a red light, her father swerved around two cars before plowing into a sport utility vehicle and a sedan, and crashing into a large concrete barrier. Stunned, Zhang gazed at the deflating airbag in front of her. She could never have imagined what was to come: Tesla Inc sued her for defamation for complaining publicly about the vehicles brakes — and won. A Chinese court ordered Zhang to pay more than US$23,000 in
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said that its investment plan in Arizona is going according to schedule, following a local media report claiming that the company is planning to break ground on its third wafer fab in the US in June. In a statement, TSMC said it does not comment on market speculation, but that its investments in Arizona are proceeding well. TSMC is investing more than US$65 billion in Arizona to build three advanced wafer fabs. The first one has started production using the 4-nanometer (nm) process, while the second one would start mass production using the
A TAIWAN DEAL: TSMC is in early talks to fully operate Intel’s US semiconductor factories in a deal first raised by Trump officials, but Intel’s interest is uncertain Broadcom Inc has had informal talks with its advisers about making a bid for Intel Corp’s chip-design and marketing business, the Wall Street Journal reported, citing people familiar with the matter. Nothing has been submitted to Intel and Broadcom could decide not to pursue a deal, according to the Journal. Bloomberg News earlier reported that Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is in early talks for a controlling stake in Intel’s factories at the request of officials at US President Donald Trump’s administration, as the president looks to boost US manufacturing and maintain the country’s leadership in critical technologies. Trump officials raised the
From George Clooney to LeBron James, celebrities in the US have cashed in on tequila’s soaring popularity, but in Mexico, producers of the agave plant used to make the country’s most famous liquor are nursing a nasty hangover. Instead of bringing a long period of prosperity for farmers of the spiky succulent, the tequila boom has created a supply glut that sent agave prices slumping. Mexican tequila exports surged from 224 million liters in 2018 to a record 402 million last year, according to the Tequila Regulatory Council, which oversees qualification for the internationally recognized denomination of origin label. The US, Germany, Spain,
RSS